How this publication decides
what to print.
Arkham Labs editorial/Published 8 September 2026/Revised 12 September 2026/Corrections policy
Published so a reader can check whether the pages follow it, and complain when they do not.
Evidence sourcing
Every factual claim traces to a peer-reviewed source with a PMID, cited inline and listed in full. Manufacturer data sheets, forum posts, blog posts, social posts, podcasts and conference abstracts are not evidence and are not cited as such. Where a claim cannot be sourced this way, it is not printed.
The grading rule
Four grades. Each has one test, applied uniformly across all sixty-eight guides. A grade describes the state of the literature. It is not a rating, not a recommendation, and not an opinion about whether a compound works. A higher grade means more has been published, not that what was published was good.
In vitro and/or animal data only. No peer-reviewed human trial has been published. This is the lowest grade available and therefore also the grade given to compounds with no published study at all — see the floor convention below.
At least one human study is indexed. This records that a study was run, not that it succeeded. Ipamorelin holds this grade on one completed randomised trial that was null on its endpoints, and the grade does not distinguish that from a positive result — the guide does.
Holds marketing authorisation from a governmental regulator in at least one jurisdiction, named in the guide along with the indication. Approval for one indication is not evidence for any other use, and several compounds at this grade are marketed off-label for something they were not approved for.
Human and preclinical data both exist and do not agree — whether because conclusions conflict by trial design, by analyst, or by indication, or because results depend on population, route or formulation. Applied to four of the most heavily studied compounds in the library. More trials has not meant more agreement.
The floor convention
Three compounds in this library — PEG-MGF and both N-acetylated variants in Family F — have no published study at any level, in any system. They are graded Preclinical because that is the lowest grade the rule provides, not because preclinical work supports them. Where this applies, the guide says so in the grade line itself: a floor, not a finding. Those chips carry a dashed edge and a “floor” mark in the library so the distinction is visible without a fifth grade.
This matters because a modified variant is routinely promoted using the parent compound’s evidence. N-Acetyl Semax Amidate is not Semax, and the record for one is not the record for the other.
What “not read for this guide” means
Several guides grade a compound Early Clinical on a human study that this publication has not read — typically Russian-language work that is indexed but not accessible in translation. Where that is the case it is stated in the grade line itself rather than left implied.
The alternative would be to either ignore an indexed study because reading it was inconvenient, or to imply an assessment that was never made. Both are worse. A grade resting on a paper nobody here has read is weaker than one resting on a paper that was read, and a reader is entitled to know which they are looking at.
Grades are set at publication and reviewed quarterly. Every change is logged in the guide’s revision history with the paper or ruling that caused it.
What is not published here
- Dosing directed at a reader. A regimen from a published study may be reported as the protocol used in that study, never as guidance.
- Before-and-after content, testimonials, transformation claims or results photography, in any format including social.
- Any claim of equivalence to an approved drug, and the phrases “clinically proven” and “pharmaceutical grade”.
- Second-person descriptions of biology. Claims sit on the evidence, not on the reader’s body.
- Coverage that treats thin evidence as strong. Where the evidence is thin, the guide says so within its first two hundred words.
Corrections
Errors are corrected in place, dated, and described in the revision history rather than quietly edited. Where a correction changes a grade, the change is also published as a field note. Where a cited paper is retracted, the claim it supported is withdrawn rather than re-sourced to something weaker.
Commercial relationships
Arkham Labs is commercially related to two businesses and earns referral revenue from links to them. This is stated on every page that contains such a link, adjacent to the link rather than in a footer. Grades, study counts and limitations are set before any commercial consideration and are not shown to those businesses before publication. Twenty-nine of sixty-eight guides in this library — including several of the best-selling compounds — carry the lowest grade in the system. The full disclosure is here.
Regulatory framing
This publication operates under US jurisdiction and treats intended use as inferred from surrounding context, consistent with FD&C Act 201(g)(1). A research-use disclaimer is not treated as protection for content that would otherwise describe a physiological effect in a person, and content is written so that no such reading is available.
For laboratory research use only. Not for human consumption. Nothing here is medical advice.